FDA Grants Traditional Approval to Encorafenib for mCRC with a BRAF V600E Mutation By Ogkologos - March 11, 2026 2 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the BREAKWATER study Source RELATED ARTICLESMORE FROM AUTHOR In Memory of Hernán Cortés-Funes: Former ESMO President and Pioneer in Medical Oncology Immune Pathways Help Identify Patients with Cancer and HIV Most Likely to Experience Reservoir Decay with Anti-PD1 Therapy Shaping Future Oncology Leaders: ESMO Broadens Its Career Development Opportunities MOST POPULAR Specific Lung Cancer Screening and Treatment Policies Urgently Needed to Address... March 23, 2022 ¿Vivir cerca de líneas eléctricas aumenta mi riesgo de desarrollar cáncer? February 23, 2023 ΚΑΡΚΙΝΟΣ ΧΟΛΗΔΟΧΟΥ ΚΥΣΤΕΩΣ March 8, 2019 NCI-MATCH Update: More Labs, New Arms, and Initial Findings November 15, 2018 Load more HOT NEWS ESMO World Congress on Gastrointestinal Cancer 2022 Barcelona, Spain 29 June... Biweekly Cabazitaxel in Patients 65 Years or Older with mCRPC for... Moving target – retrotransposable elements and cancer El cáncer en mi comunidad: Ampliar el acceso a las pruebas...
